PureTech Health plc has made no secret of its ambition to use Karuna Therapeutics, Inc. as a blueprint for the development of new portfolio companies. In Seaport Therapeutics, which formally launched yesterday with a $100m series A round, it is doing exactly that.
PureTech Hopes For A Second Lightning Strike
Emerging Company Profile: Seaport Therapeutics believes its technology can alter old drugs to remove their flaws. Just how closely can it follow the example set by Karuna?
